Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Relapsing-Remitting Multiple Sclerosis peptide trials
3 selected ClinicalTrials.gov records carrying the official condition label Relapsing-Remitting Multiple Sclerosis. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
3 selected records.
1 profiles.
2015–2020 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 25 selected PubMed records and 11 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Relapsing-Remitting Multiple Sclerosis unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT00203021
PeptideScanner retained ClinicalTrials.gov record NCT00203021 at 2026-11-16T17:42:50.457Z. Its registry update date was 2020-02-18, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- February 18, 2020
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT00451451
PeptideScanner retained ClinicalTrials.gov record NCT00451451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-01-26, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- January 26, 2015
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT01874145
PeptideScanner retained ClinicalTrials.gov record NCT01874145 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-01-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- January 14, 2016
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Glatiramer acetate · 2020-02-18
ClinicalTrials.gov record NCT00203021
Completed at the retained observation.
Open attributed record →Glatiramer acetate · 2016-01-14
ClinicalTrials.gov record NCT01874145
Completed at the retained observation.
Open attributed record →Glatiramer acetate · 2015-01-26
ClinicalTrials.gov record NCT00451451
Completed at the retained observation.
Open attributed record →